fda panel review genentech tpa federal food drug administration fda expect announce soon require additional review genentech tpa heart drug move delay company plan market drug spring government wall street source tpa bioengineered bloodclot dissolve drug genentech hope market name activase review fda cardiorenal advisory committee panel meet source neither genentech fda confirm review drug set consideration meet fda official draft agenda similarly genentech spokeswoman fda notify advisory committee review possibility minute confirm agenda spokeswoman review possibility decline review affect market plan receive official fda word spokeswoman acknowledge rumor fda committee review buffet genentech stock yesterday wall street stock fell dollar share clsoe dollar tpa stand tissue plasminogen activator heart attack victim blockage vein artery blood clot dissolver market tpa effective fewer effect analyst project worldwide market drug dollar stuart weisbrod biotechnology analyst prudential bache security 
s additional fda review tpa market november approval expect spring fda action prompt cut estimate genentech earn cent share earlier projection cent share delay lower genentech revenue tpa million dollar compare earlier projection million dollar revenue 
